Moody Aldrich Partners’s Transmedics TMDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-25,733
Closed -$4.04M – 220
2024
Q3
$4.04M Sell
25,733
-448
-2% -$69K 0.73% 62
2024
Q2
$3.94M Sell
26,181
-8,349
-24% -$1M 0.77% 61
2024
Q1
$2.55M Sell
34,530
-11,782
-25% -$971K 0.43% 85
2023
Q4
$3.66M Buy
46,312
+24,290
+110% +$1.47M 0.66% 68
2023
Q3
$1.21M Sell
22,022
-5,839
-21% -$420K 0.23% 109
2023
Q2
$2.34M Sell
27,861
-141
-0.5% -$10.8K 0.45% 86
2023
Q1
$2.12M Buy
+28,002
New +$1.94M 0.43% 87
2022
Q3
– Sell
-106,798
Closed -$3.36M – 173
2022
Q2
$3.36M Sell
106,798
-81,523
-43% -$2.17M 0.66% 68
2022
Q1
$5.07M Buy
188,321
+22,243
+13% +$399K 0.71% 55
2021
Q4
$3.18M Buy
166,078
+32,209
+24% +$807K 0.44% 79
2021
Q3
$4.43M Buy
+133,869
New +$4.09M 0.56% 75

Other funds holding TMDX

Moody Aldrich Partners's TMDX Position: Q4 2024 in Review

Moody Aldrich Partners sold out of Transmedics (TMDX) in Q4 2024, closing a stake of 25,733 shares — an estimated $4.04M sold.

Moody Aldrich Partners first reported a position in TMDX in Q3 2021 and held it in 11 quarters. The position peaked at $5.07M in Q1 2022. 315 funds tracked by Wall St. Rank hold TMDX as of Q4 2024.

  • Moody Aldrich Partners reported no remaining Transmedics position as of Q4 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 25,733 Transmedics shares in Q4 2024, an estimated $4.04M.
  • Moody Aldrich Partners first reported a position in Transmedics in Q3 2021 and held it in 11 quarters.
  • Moody Aldrich Partners's Transmedics position peaked at $5.07M in Q1 2022.
  • 315 funds tracked by Wall St. Rank held Transmedics as of Q4 2024.

Based on Moody Aldrich Partners's 13F filing for Q4 2024, filed 23 Jan 2025.